Reactivation of hepatitis B virus infection with persistently negative HBsAg on three HBsAg assays in a lymphoma patient undergoing chemotherapy
- PMID: 20031483
- DOI: 10.1016/j.jcv.2009.11.024
Reactivation of hepatitis B virus infection with persistently negative HBsAg on three HBsAg assays in a lymphoma patient undergoing chemotherapy
Abstract
In patients with occult hepatitis B virus (HBV) infection, acute exacerbation may occur when they become immunocompromised. Usually, these patients develop hepatitis B surface antigen (HBsAg) seroreversion during the flare. Here we report on a patient with occult HBV infection, who developed HBV exacerbation after chemotherapy for diffuse large B-cell lymphoma. The resurgence of HBV DNA preceded the elevation of liver enzymes for 20 weeks. Atypically, despite high viraemia, serological tests showed persistently negative HBsAg using three different sensitive HBsAg assays (i.e., Architect, Murex and AxSYM). On comparing the amino acid sequence of the index patient with the consensus sequence, five mutations were found at pre-S1, five at pre-S2 and twenty-three mutations at the S region. Six amino acid mutations were located in the 'a' determinant, including P120T, K122R, M133T, F134L, D144A and G145A. The mutants K122R, F134L and G145A in our patient have not been tested for their sensitivity to Architect and Murex assays by the previous investigators and might represent the escape mutants to these assays.
Similar articles
-
Immunocompromised patients with HBsAg a determinant mutants: comparison of HBsAg diagnostic assays.Intervirology. 2010;53(3):183-7. doi: 10.1159/000289342. Epub 2010 Mar 3. Intervirology. 2010. PMID: 20197685
-
Fatal reactivation of hepatitis B virus in a patient who was hepatitis B surface antigen negative and core antibody positive before receiving chemotherapy for non-Hodgkin lymphoma.J Clin Gastroenterol. 2009 May-Jun;43(5):496-8. doi: 10.1097/MCG.0b013e3181945942. J Clin Gastroenterol. 2009. PMID: 19247200
-
Molecular characterization of a variant virus that caused de novo hepatitis B without elevation of hepatitis B surface antigen after chemotherapy with rituximab.J Med Virol. 2008 Dec;80(12):2069-78. doi: 10.1002/jmv.21311. J Med Virol. 2008. PMID: 19040281
-
Occult hepatitis B virus infection: implications in transfusion.Vox Sang. 2004 Feb;86(2):83-91. doi: 10.1111/j.0042-9007.2004.00406.x. Vox Sang. 2004. PMID: 15023176 Review.
-
Occult hepatitis B virus infection.Transfus Clin Biol. 2004 Feb;11(1):18-25. doi: 10.1016/j.tracli.2003.11.007. Transfus Clin Biol. 2004. PMID: 14980545 Review.
Cited by
-
Detection of circulating hepatitis B virus immune escape and polymerase mutants among HBV-positive patients attending Institut Pasteur de Bangui, Central African Republic.Int J Infect Dis. 2020 Jan;90:138-144. doi: 10.1016/j.ijid.2019.10.039. Epub 2019 Nov 1. Int J Infect Dis. 2020. PMID: 31682960 Free PMC article.
-
Roles of Hepatitis B Virus Mutations in the Viral Reactivation after Immunosuppression Therapies.Viruses. 2019 May 19;11(5):457. doi: 10.3390/v11050457. Viruses. 2019. PMID: 31109119 Free PMC article. Review.
-
Mutations associated with occult hepatitis B in HIV-positive South Africans.J Med Virol. 2015 Mar;87(3):388-400. doi: 10.1002/jmv.24057. Epub 2014 Aug 27. J Med Virol. 2015. PMID: 25164924 Free PMC article.
-
Occult Hepatitis B (OBH) in Clinical Settings.Hepat Mon. 2012 Aug;12(8):e6126. doi: 10.5812/hepatmon.6126. Epub 2012 Aug 25. Hepat Mon. 2012. PMID: 23087749 Free PMC article.
-
Impaired virion secretion by hepatitis B virus immune escape mutants and its rescue by wild-type envelope proteins or a second-site mutation.J Virol. 2013 Feb;87(4):2352-7. doi: 10.1128/JVI.02701-12. Epub 2012 Dec 5. J Virol. 2013. PMID: 23221548 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical